

Tegsedi[®] (inotersen) Medication Precertification Request

Page 1 of 1

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY: 711)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate:		_	/ / of last treatment	1 1				
		• •				F		
Precertification Req				Phone:		Fax:		
A. PATIENT INFORM	MATION		Last Name			DOD:		
First Name:			Last Name:	0::		DOB:	710	
Address:	T			City:		State:	ZIP:	
Home Phone:		Vork Phone:		Cell Phone:		Email:		
Current Weight:		Height:	inches orcn	ns Allergies:				
B. INSURANCE INFO					s 🗌 No			
Aetna Member ID #:			Does patient have other					
Group #: nsured:			If yes, provide ID#: Carrier Name: Insured:					
	7 N	ID #.		disside DV DN-	16	: ID #.		
Medicare: Yes		#: * ID #:	ivie	dicaid: Yes No	ii yes, provi	ide ID #:		
C. PRESCRIBER INF First Name:	-ORMATION		Last Name:		Check One:		D.O. N.P.	ПРА
Address:			Last Name.	City:	DITECK OTTE.	State:	ZIP:	<u> </u>
Phone:	Fax:		St Lic #:	NPI #:	DEA #:	State.	UPIN:	
Provider Email:	гах.		Office Contact Name:	INPI #.	DEA #.	Phone:	UPIN.	
Specialty (Check one)		Other: _						
D. DISPENSING PRO		RATION INFO	RMATION					
Place of Administration: ☐ Self-administered ☐ Physician's Office				Dispensing Provider/Pharmacy: (Patient selected choice) ☐ Physician's Office ☐ Retail Pharmacy				
☐ Outpatient Infusion	-			Specialty Pharmacy Other: Name:				
	:							
☐ Home Infusion Cen			Address:					
	e:							
☐ Administration code				Phone: Fax:				
Address:			11N:		PIN:			
E. PRODUCT INFOR				_				
Request is for: Tegseo	* *			Frequency:				
		indicate prima	ry ICD code and specif	y any other where applic				
Primary ICD Code:				Other ICD Code:				
	· · · · · · · · · · · · · · · · · · ·		ation must be complete	ed in its <u>entirety</u> for all pr	ecertificatior	requests.		
For All Requests (cli								
			-	yretin-type familial am	nyloid polyr	europathy	[ATTR-FAP])	
	•	•	ion of a mutation in the	•	ratin madia	tad amulaida	oio (ATTD EAD)	
Yes No Does the patient exhibit clinical manifestations of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTR-FAP) (e.g., amyloid deposition in biopsy specimens, TTR protein variants in serum, progressive peripheral sensory-motor polyneuropathy)?								
☐ Yes ☐ No Will t	he requested medic	ation be used	in combination with any	other medication appro /yndamax, Vyndaqel, W	ved for the t	-		,
☐ Yes ☐ No Will t	-	ation be presc	ribed by or in consultati	on with any of the follow	-	ologist, b) G	eneticist, or	
For Continuation Re	quests (clinical doc	umentation re	quired for all requests)	<u>.</u>				
neur comp	opathy severity and	rate of disease folk Quality of	e progression as demon	uested medication comp strated by the modified ny (QoL-DN) total score	Neuropathy	Impairment:	Ścale+7 (mNIS+	
H. ACKNOWLEDGE	MENT							
Request Completed	By (Signature Reg	uired):				Dat	e: / /	<u> </u>
-		-	tion of coverage of a m	edical procedure or ser	vice with the			

any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent

insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.